Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

The Liposome Company Plans Product In-Licensing To Combat Evacet Delays

Executive Summary

The Liposome Company plans to buy or in-license a product from another company to compensate for delays in the approval of Evacet for the treatment of metastatic breast cancer, CEO Charles Baker told analysts.

You may also be interested in...



The Liposome Company Moves Past Evacet Set-Backs With Elan Merger

Elan would add a 40 rep oncology sales force to market its non-opioid analgesic ziconotide with the acquisition of The Liposome Company announced March 6.

The Liposome Company Moves Past Evacet Set-Backs With Elan Merger

Elan would add a 40 rep oncology sales force to market its non-opioid analgesic ziconotide with the acquisition of The Liposome Company announced March 6.

The Liposome Company Evacet

Additional clinical data will be needed to gain FDA approval for metastatic breast cancer based on discussions with FDA, company says Feb. 3. The company is considering foregoing the metastatic indication in favor of pursuing a lymphoma indication. The company had submitted analyses to FDA to support resubmission of the Evacet application following withdrawal of the original application (1"The Pink Sheet" Oct. 18, 1999, In Brief)

UsernamePublicRestriction

Register

RS150923

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel